Post hoc analysis of pembrolizumab for advanced MSI-H gastric or gastroesophageal junction cancer
Dr. Joseph Chao
Post hoc analysis of three prospective studies found that pembrolizumab with or without chemotherapy was more beneficial than chemotherapy alone for the treatment of patients who had microsatellite instability-high advanced or metastatic gastric or gastroesophageal junction cancer, across all lines of therapy. MSI-H status may be a biomarker for pembrolizumab therapy among patients with advanced G/GEJ cancer regardless of the line of therapy.
